Skip to main content
Erschienen in: Journal of Neurology 6/2012

01.06.2012 | Original Communication

Factors related to recurrence of paradoxical cerebral embolism due to patent foramen ovale

verfasst von: Takuya Fukuoka, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ohe Yasuko, Ichiro Deguchi, Hajime Maruyama, Yohsuke Horiuchi, Hidetaka Takeda, Norio Tanahashi

Erschienen in: Journal of Neurology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Patent foramen ovale (PFO) is an important etiology of ischemic stroke in young adults. We investigated factors contributing to recurrent ischemic stroke in patients with PFO. Subjects comprised 47 patients (mean age, 56.8 ± 14.2 years; range 23–74 years) with ischemic stroke due to PFO who were admitted to our hospital between April 2007 and February 2011. Mean duration of follow-up was 34.5 ± 13 months. Recurrence occurred in 11 cases. Annual recurrence rate was 23.4%. We investigated relationships between recurrence of ischemic stroke and size of PFO (large, >4 mm; medium, 2–3.9 mm; small, <1.9 mm; absent group), maximal number of microbubbles (determined as the number of microembolic signals: small, 0–5; moderate, 6–25; and multiple, ≥26), massive bubble on contrast transesophageal echocardiography or atrial septal aneurysm, D-dimer level and antithrombotic therapy. Univariate analysis showed size of the PFO (P = 0.013), number of microbubbles (P = 0.021), and presence of a massive bubble on echocardiography (P = 0.04) were related to recurrence of ischemic stroke. Logistic analysis identified size of the PFO (P < 0.05) and massive bubble on echocardiography (P < 0.05) as factors related to recurrence of ischemic stroke. In conclusion, size of the PFO and presence of a massive bubble were considered to be factors associated with recurrence of ischemic stroke due to PFO.
Literatur
1.
Zurück zum Zitat Schneider B, Zienkiewicz T, Jansen V, Hofmann T, Noltenius H, Meinertz T (1996) Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings. Am J Cardiol 77(14):1202–1209. pii: S0002-9149(96)00163-4PubMedCrossRef Schneider B, Zienkiewicz T, Jansen V, Hofmann T, Noltenius H, Meinertz T (1996) Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings. Am J Cardiol 77(14):1202–1209. pii: S0002-9149(96)00163-4PubMedCrossRef
2.
Zurück zum Zitat Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332(25):1661–1665. doi:10.1056/NEJM199506223322501 PubMedCrossRef Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332(25):1661–1665. doi:10.​1056/​NEJM199506223322​501 PubMedCrossRef
3.
Zurück zum Zitat Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336(6):393–398. doi:10.1056/NEJM199702063360601 PubMedCrossRef Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336(6):393–398. doi:10.​1056/​NEJM199702063360​601 PubMedCrossRef
4.
Zurück zum Zitat Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907. doi:10.1056/NEJM199903253401201 PubMedCrossRef Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907. doi:10.​1056/​NEJM199903253401​201 PubMedCrossRef
5.
Zurück zum Zitat Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345(3):165–169. doi:10.1056/NEJM200107193450302 PubMedCrossRef Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345(3):165–169. doi:10.​1056/​NEJM200107193450​302 PubMedCrossRef
6.
Zurück zum Zitat Schneider B, Hofmann T, Justen MH, Meinertz T (1995) Chiari’s network: normal anatomic variant or risk factor for arterial embolic events? J Am Coll Cardiol 26(1):203–210. pii: 073510979500144OPubMedCrossRef Schneider B, Hofmann T, Justen MH, Meinertz T (1995) Chiari’s network: normal anatomic variant or risk factor for arterial embolic events? J Am Coll Cardiol 26(1):203–210. pii: 073510979500144OPubMedCrossRef
7.
Zurück zum Zitat Steiner MM, Di Tullio MR, Rundek T, Gan R, Chen X, Liguori C, Brainin M, Homma S, Sacco RL (1998) Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 29(5):944–948PubMedCrossRef Steiner MM, Di Tullio MR, Rundek T, Gan R, Chen X, Liguori C, Brainin M, Homma S, Sacco RL (1998) Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 29(5):944–948PubMedCrossRef
8.
Zurück zum Zitat Schuchlenz HW, Weihs W, Horner S, Quehenberger F (2000) The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 109(6):456–462PubMedCrossRef Schuchlenz HW, Weihs W, Horner S, Quehenberger F (2000) The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 109(6):456–462PubMedCrossRef
9.
Zurück zum Zitat Mas JL, Zuber M (1995) Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 130(5):1083–1088PubMedCrossRef Mas JL, Zuber M (1995) Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 130(5):1083–1088PubMedCrossRef
10.
Zurück zum Zitat Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345(24):1740–1746. doi:10.1056/NEJMoa011503 PubMedCrossRef Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345(24):1740–1746. doi:10.​1056/​NEJMoa011503 PubMedCrossRef
11.
Zurück zum Zitat Nedeltchev K, Arnold M, Wahl A, Sturzenegger M, Vella EE, Windecker S, Meier B, Mattle HP (2002) Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 72(3):347–350PubMedCrossRef Nedeltchev K, Arnold M, Wahl A, Sturzenegger M, Vella EE, Windecker S, Meier B, Mattle HP (2002) Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 72(3):347–350PubMedCrossRef
12.
Zurück zum Zitat Kato Y, Dembo T, Takeda H, Fukuoka T, Tanahashi N (2011) Prominent persisting Eustachian valve initiates spontaneous right-to-left shunt and paradoxical embolism in a patient with patent foramen ovale. Neurol Sci. doi:10.1007/s10072-011-0567-7 PubMed Kato Y, Dembo T, Takeda H, Fukuoka T, Tanahashi N (2011) Prominent persisting Eustachian valve initiates spontaneous right-to-left shunt and paradoxical embolism in a patient with patent foramen ovale. Neurol Sci. doi:10.​1007/​s10072-011-0567-7 PubMed
13.
Zurück zum Zitat Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP (2003) Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol 42(6):1066–1072. pii: S0735109703009070PubMedCrossRef Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP (2003) Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol 42(6):1066–1072. pii: S0735109703009070PubMedCrossRef
14.
Zurück zum Zitat Yasaka M, Ikeno K, Otsubo R, Oe H, Nagano K, Minematsu K (2005) Right-to-left shunt evaluated at the aortic arch by contrast-enhanced transesophageal echocardiography. J Ultrasound Med 24(2):155–159. pii: 24/2/155PubMed Yasaka M, Ikeno K, Otsubo R, Oe H, Nagano K, Minematsu K (2005) Right-to-left shunt evaluated at the aortic arch by contrast-enhanced transesophageal echocardiography. J Ultrasound Med 24(2):155–159. pii: 24/2/155PubMed
15.
Zurück zum Zitat Yasaka M, Otsubo R, Oe H, Minematsu K (2005) Is stroke a paradoxical embolism in patients with patent foramen ovale? Intern Med 44(5):434–438. pii: JST.JSTAGE/internalmedicine/44.434 PubMedCrossRef Yasaka M, Otsubo R, Oe H, Minematsu K (2005) Is stroke a paradoxical embolism in patients with patent foramen ovale? Intern Med 44(5):434–438. pii: JST.JSTAGE/internalmedicine/44.434 PubMedCrossRef
16.
Zurück zum Zitat Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105(22):2625–2631PubMedCrossRef Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP (2002) Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105(22):2625–2631PubMedCrossRef
Metadaten
Titel
Factors related to recurrence of paradoxical cerebral embolism due to patent foramen ovale
verfasst von
Takuya Fukuoka
Tomohisa Dembo
Harumitu Nagoya
Yuji Kato
Ohe Yasuko
Ichiro Deguchi
Hajime Maruyama
Yohsuke Horiuchi
Hidetaka Takeda
Norio Tanahashi
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 6/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6297-1

Weitere Artikel der Ausgabe 6/2012

Journal of Neurology 6/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.